Arcturus COVID-19 vaccine

Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19

Retrieved on: 
Monday, August 2, 2021
Health, Infectious diseases, Manufacturing, Genetics, Other Manufacturing, Pharmaceutical, Nucleic acids, COVID-19 vaccines, Clinical trials, RNA vaccines, Moderna COVID-19 vaccine, COVID-19 vaccine, Vaccine, Messenger RNA, Arcturus Therapeutics, Arcturus COVID-19 vaccine

Arcturus will provide Vinbiocare with an exclusive license to manufacture the vaccines in Vietnam at the facility solely for distribution in Vietnam.

Key Points: 
  • Arcturus will provide Vinbiocare with an exclusive license to manufacture the vaccines in Vietnam at the facility solely for distribution in Vietnam.
  • The license and technology transfer applies toward drug product manufacturing but not toward mRNA drug substance manufacturing.
  • Vinbiocare will also pay for mRNA drug substance supplied by Arcturus and royalties on vaccines produced at the Facility.
  • Arcturus investigational COVID-19 vaccines utilize Arcturus self-transcribing and replicating (STARR) mRNA technology, and the STARR mRNA is delivered with Arcturuss lipid-mediated delivery system called LUNAR delivery system.

The Asia Group Serves as Key Strategic and Sales Advisor to Groundbreaking Collaboration Agreement to Bring mRNA Vaccine Technology to Vietnam

Retrieved on: 
Monday, August 2, 2021
Marketing strategy, Merchandising, Retail

We look forward to continuing to work with the TAG team as we look for new opportunities to expand our business."

Key Points: 
  • We look forward to continuing to work with the TAG team as we look for new opportunities to expand our business."
  • The Asia Group is the premier strategic advisory firm to the world's leading companies seeking to excel across the Indo-Pacific.
  • Vingroupis the largest private enterprise in Vietnam, with a market capitalization exceeding USD 21 billion and USD 4.7 billion in annual sales.
  • Founded in 1993, Vingroup's operations include a diversified portfolio of investments in real estate, retail, automotive manufacturing, and scientific research.

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Retrieved on: 
Tuesday, July 6, 2021
Health, Infectious diseases, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Nucleic acids, Branches of biology, RNA, Molecular biology, Gene expression, Biotechnology, Arcturus Therapeutics, RNA therapeutics, Small interfering RNA, Sense, Arcturus COVID-19 vaccine, RNA vaccine

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.
  • Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

Retrieved on: 
Wednesday, June 9, 2021
Health, Infectious diseases, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Nucleic acids, Branches of biology, RNA, Molecular biology, Gene expression, Biotechnology, Arcturus Therapeutics, RNA therapeutics, Small interfering RNA, Sense, Arcturus COVID-19 vaccine, RNA vaccine

Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.

Key Points: 
  • Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in upcoming investor and scientific conferences.
  • Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).

Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data

Retrieved on: 
Monday, May 10, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Nucleic acids, Branches of biology, RNA, COVID-19 vaccines, Clinical trials, Arcturus COVID-19 vaccine, RNA vaccine, RNA therapeutics, Messenger RNA

We believe that ARCT-021, as a single shot lyophilized self-amplifying mRNA vaccine, if approved, may represent a preferred vaccine option.

Key Points: 
  • We believe that ARCT-021, as a single shot lyophilized self-amplifying mRNA vaccine, if approved, may represent a preferred vaccine option.
  • We are very pleased with the recent successes in our mRNA drug product manufacturing efforts, and in the expansion of our global safety database \xe2\x80\x93 and the positive readthrough this provides to the Company\xe2\x80\x99s pipeline of mRNA therapeutics.
  • The primary driver of the sequential increase was driven by higher clinical and manufacturing cost of $17.2 million for our ARCT-021 program.
  • Based on our current plans, the Company\xe2\x80\x99s cash position is expected to be sufficient to support operations for more than two years.\nMonday, May 10th @ 4:30 p.m. ET\n'